(R)-(-)-tert-butyl 4-((2,3-dimethoxyphenyl)(hydroxy)methyl)piperidine-1-carboxylate | 243640-25-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-(-)-tert-butyl 4-((2,3-dimethoxyphenyl)(hydroxy)methyl)piperidine-1-carboxylate
• 英文别名: (R)-4-(1-hydroxy-1-(2,3-dimethoxyphenyl)methyl)-1-piperidinecarboxylic acid, 1,1-dimethylethyl ester；tert-butyl 4-[(R)-(2,3-dimethoxyphenyl)-hydroxymethyl]piperidine-1-carboxylate
• CAS: 243640-25-7
• 化学式: C₁₉H₂₉NO₅
• 分子量: 351.443
• InChiKey: INENTLDQGORLJP-MRXNPFEDSA-N

物化性质

• 沸点：
  474.2±40.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  68.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-叔丁氧羰基-(2,3-二甲氧基苯基)-4-哌啶基甲酮 在 9-O-(1,2-isopropylidene-5-deoxy-α-D-xylofuranosyl)-9-borabicyclo[3.3.1]nonane 、 potassium hydride 作用下， 以 四氢呋喃 为溶剂， 以63%的产率得到(R)-(-)-tert-butyl 4-((2,3-dimethoxyphenyl)(hydroxy)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol"

  摘要：

  本发明提供了制备(R)-α-(2,3-二甲氧基苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的各种工艺。这些工艺可由以下方案描述：

  公开号：

  EP1734037A3

文献信息

• Highly enantioselective hydrogenation and transfer hydrogenation of cycloalkyl and heterocyclic ketones catalysed by an iridium complex of a tridentate phosphine-diamine ligand
  作者：José A. Fuentes、Ian Carpenter、Nina Kann、Matthew L. Clarke

  DOI：10.1039/c3cc45545a

  日期：——

  Ir complexes of chiral phosphine-diamine ligands catalyse the hydrogenation and transfer hydrogenation of aryl-piperidin-4-yl methanones, and ketones bearing both an aryl group and secondary alkyl substituent with up to 98% e.e., and with substrate to catalyst ratios of up to 4000.

  手性膦-二胺配体的Ir配合物催化芳基-哌啶-4-基甲酮和带有芳基和仲烷基取代基且具有ee高达98％的底物与催化剂的比率最高的酮的氢化和转移氢化到4000。
• Methods for identifying novel multimeric agents that modulate receptors
  申请人：——

  公开号：US20030087306A1

  公开（公告）日：2003-05-08

  Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same of different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

  本发明揭示了新型的多重结合化合物（试剂），其能够结合细胞受体。本发明的化合物包括多个配体，每个配体都能够结合到这些细胞受体上，从而调节其生物过程/功能。每个配体均与一个连接剂或连接剂共价结合，这些连接剂可以相同或不同，以提供多重结合化合物。所选择的连接剂使得所构建的多重结合化合物表现出对细胞生物过程/功能的增强调节或干扰。本发明还揭示了一种识别能够结合细胞受体的新型多重结合化合物的方法，以及一种生成这种新型多重结合化合物混合物的方法。
• NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
  申请人：Laux Wolfgang

  公开号：US20090227798A1

  公开（公告）日：2009-09-10

  The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:

  本发明提供了制备（R）-α-（2,3-二甲氧基苯基）-1-[2-（4-氟苯基）乙基]-4-哌啶甲醇的各种方法。这些方法可以通过以下方案进行表征：
• MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT2 RECEPTORS
  申请人：Advanced Medicine, Inc.

  公开号：EP1107753A1

  公开（公告）日：2001-06-20
• [EN] MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT2 RECEPTORS<br/>[FR] AGONISTES POLYVALENTS, AGONISTES PARTIELS, AGONISTES INVERSES ET ANTAGONISTES DES RECEPTEURS 5HT2
  申请人：ADVANCED MEDICINE INC

  公开号：WO1999063996A1

  公开（公告）日：1999-12-16

  Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the 5HT2 receptors, which are involved in neurological disorders. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is an agonist, partial agonist, inverse agonist or antagonist of the 5HT2 receptors. The multibinding compounds of this invention are useful for the prophylaxis and treatment of various neurological disorders such as depression, anxiety, epilepsy, psychosis, schizophrenia, Alzheimer's disease, drug addiction, sleep and eating disorders, migraine and pain.